Adaptive Biotechnologies is trading at $27.33 (+10.29%) today. - The surge is driven by investor enthusiasm following management's updates at the Morgan Stanley 24th Annual Global Healthcare Conference fireside chat, where progress on separating its MRD and Immune Medicine units was outlined. - Optimism for a more focused diagnostics strategy and strong second-quarter results are also contributing to the rally. - This company-specific interest is noted amid weaker broader markets and the biotech sector.